Table 1 Basal characteristics of the study patients according to the induction regimen.
Variables | Unadjusted | Adjusted | |||||||
|---|---|---|---|---|---|---|---|---|---|
Basiliximab | Low dose ATG | High dose ATG | P-value | SMD | Basiliximab | Low dose ATG | High dose ATG | SMD | |
(n = 3655) | (n = 467) | (n = 457) | (n = 3655) | (n = 467) | (n = 457) | ||||
Recipient characteristics | |||||||||
Age, years | 48.9 ± 11.6 | 51.4 ± 10.7 | 51.1 ± 10.8 | < 0.001 | 0.222 | 49.2 ± 12.8 | 49.8 ± 29.9 | 49.4 ± 31.3 | 0.074 |
Female sex | 1362 (37.3) | 208 (44.5) | 258 (56.5) | < 0.001 | 0.392 | (39.1) | (39.7) | (42.3) | 0.116 |
Body mass index, kg/m2 | 23.2 ± 3.6 | 23.5 ± 3.4 | 22.6 ± 3.1 | < 0.001 | 0.267 | 23.1 ± 3.9 | 23.8 ± 10.1 | 22.9 ± 8.8 | 0.066 |
Hypertension | 3303 (90.4) | 412 (88.2) | 400 (87.5) | 0.076 | 0.094 | (90.3) | (86.8) | (87.9) | 0.055 |
Diabetes mellitus | 1119 (30.6) | 152 (32.6) | 137 (30.0) | 0.648 | 0.058 | (30.7) | (29.7) | (32.3) | 0.060 |
Primary cause of ESRD | |||||||||
Diabetes mellitus | 885 (24.2) | 121 (25.9) | 109 (23.9) | 0.577 | 0.055 | (23.9) | (24.3) | (26.2) | 0.090 |
Hypertension | 542 (14.8) | 69 (14.8) | 81 (17.7) | (15.1) | (15.6) | (21.2) | |||
Glomerulonephritis | 1192 (32.6) | 165 (35.5) | 151 (33.0) | (32.3) | (37.0) | (30.7) | |||
Tubulointerstitial nephritis | 14 (0.4) | 2 (0.4) | 2 (0.4) | (0.4) | (0.4) | (0.7) | |||
Polycystic kidney disease | 182 (5.0) | 20 (4.3) | 24 (5.3) | (5.0) | (4.4) | (4.5) | |||
Hereditary kidney disease except PCKD | 52 (1.4) | 3 (0.6) | 4 (0.9) | (1.4) | (0.6) | (0.8) | |||
Obstructive uropathy | 17 (0.5) | 0 (0) | 0 (0) | (0.5) | (0.0) | (0.0) | |||
Others | 37 (1.0) | 2 (0.4) | 4 (0.9) | (1.1) | (0.4) | (0.9) | |||
Unknown | 734 (20.1) | 85 (18.2) | 82 (17.9) | (20.4) | (17.4) | (15.0) | |||
Previous transplant | 198 (5.4) | 67 (14.4) | 74 (16.2) | < 0.001 | 0.412 | (6.9) | (7.9) | (9.3) | 0.108 |
Preemptive transplant | 600 (16.4) | 46 (9.9) | 49 (10.7) | < 0.001 | 0.183 | (15.3) | (16.0) | (15.8) | 0.034 |
ABO-incompatible KT | 651 (17.8) | 71 (15.2) | 57 (12.5) | 0.009 | 0.142 | (16.9) | (18.8) | (17.9) | 0.042 |
ABDR mismatch | 3.91 ± 1.17 | 4.18 ± 1.16 | 4.17 ± 1.13 | < 0.001 | 0.234 | 3.94 ± 1.30 | 3.98 ± 3.32 | 4.02 ± 3.11 | 0.073 |
DR mismatch | 1.29 ± 0.50 | 1.40 ± 0.52 | 1.39 ± 0.51 | < 0.001 | 0.225 | 1.30 ± 0.56 | 1.32 ± 1.39 | 1.34 ± 1.33 | 0.079 |
Panel reactive antibody, % | |||||||||
PRA1 | 9.2 ± 20.8 | 16.2 ± 27.0 | 22.0 ± 31.2 | < 0.001 | 0.210 | 10.5 ± 25.0 | 13.9 ± 66.1 | 14.8 ± 71.0 | 0.097 |
PRA2 | 9.2 ± 21.5 | 15.2 ± 28.0 | 23.3 ± 32.7 | < 0.001 | 0.201 | 10.5 ± 25.8 | 12.6 ± 67.1 | 14.80 ± 74.0 | 0.104 |
Pre-transplant DSA | 249 (6.8) | 89 (19.1) | 143 (31.3) | < 0.001 | 0.056 | (9.2) | (13.4) | (13.8) | 0.082 |
Missing | 1325 (36.3) | 147 (31.5) | 104 (22.8) | (35.1) | (35.1) | (32.1) | |||
Desensitization | 779 (21.3) | 133 (28.5) | 160 (35.0) | < 0.001 | 0.322 | (23.0) | (26.0) | (24.6) | 0.070 |
Calcineurin inhibitor | 3641 (99.6) | 465 (99.6) | 456 (99.8) | 0.843 | 0.034 | (99.6) | (99.7) | (99.8) | 0.031 |
Tacrolimus | 3524 (96.4) | 456 (97.6) | 454 (99.3) | 0.002 | (96.5) | (97.0) | (98.6) | ||
Cyclosporine | 117 (3.2) | 9 (1.9) | 2 (0.4) | 0.002 | (3.2) | (2.7) | (1.2) | ||
Mycophenolate mofetil | 3454 (94.5) | 453 (97.0) | 441 (96.5) | 0.019 | 0.114 | (94.7) | (98.3) | (98.3) | 0.164 |
Sirolimus or everolimus | 15 (0.4) | 1 (0.2) | 2 (0.4)) | 0.913 | 0.036 | (0.4) | (0.1) | (0.3) | 0.054 |
Steroid | 3623 (99.1) | 460 (98.5) | 439 (96.1) | < 0.001 | 0.276 | (99.0) | (97.2) | (98.6) | 0.162 |
Donor characteristics | |||||||||
Age, years | 47.1 ± 12.8 | 48.9 ± 13.4 | 47.7 ± 13.4 | 0.018 | 0.135 | 47.3 ± 14.3 | 47.6 ± 34.1 | 48.1 ± 35.0 | 0.067 |
Female sex | 1846 (50.5) | 183 (39.2) | 170 (37.2) | < 0.001 | 0.266 | (48.5) | (46.9) | (47.8) | 0.042 |
Body mass index, kg/m2 | 23.9 ± 3.3 | 24.0 ± 3.5 | 23.8 ± 3.6 | 0.521 | 0.074 | 23.9 ± 3.7 | 23.8 ± 8.8 | 24.0 ± 8.9 | 0.056 |
Relation to the recipient | |||||||||
Deceased donor | 1193 (32.6) | 269 (57.6) | 247 (54.1) | < 0.001 | 0.388 | (36.4) | (38.0) | (40.4) | 0.082 |
Living, related | 1434 (39.2) | 94 (20.1) | 113 (24.7) | (36.7) | (32.4) | (33.9) | |||
Living, unrelated | 1028 (28.1) | 104 (22.3) | 97 (21.2) | (26.9) | (29.7) | (26.3) | |||
CRRT | 51 (1.4) | 34 (7.3) | 18 (3.9) | < 0.001 | 0.467 | (1.7) | (3.5) | (2.3) | 0.119 |
Missing | 2528 (69.2) | 207 (44.3) | 218 (47.7) | (65.5) | (64.0) | (60.7) | |||
Current smoker | 2452 (67.1) | 270 (57.8) | 270 (59.1) | < 0.001 | 0.195 | (65.7) | (66.1) | (65.4) | 0.032 |
Hypertension | 515 (14.1) | 94 (20.1) | 92 (20.1) | < 0.001 | 0.206 | (14.9) | (17.2) | (18.0) | |
Serum creatinine, mg/dL | 0.95 ± 0.70 | 1.41 ± 1.32 | 1.46 ± 1.39 | < 0.001 | 0.569 | 1.03 ± 0.94 | 1.04 ± 2.36 | 1.07 ± 2.46 | 0.073 |
Cold ischemic time | |||||||||
0–6 h | 2812 (76.9) | 341 (73.0) | 316 (69.2) | < 0.001 | 0.137 | (76.0) | (78.2) | (74.5) | 0.058 |
6–12 h | 192 (5.3) | 47 (10.1) | 41 (9.0) | (6.0) | (570.0) | (6.4) | |||
> 12 h | 6 (0.2) | 5 (1.1) | 2 (0.4) | (0.2) | (0.5) | (0.2) | |||
Missing | 645 (17.7) | 74 (15.9) | 98 (21.4) | (17.8) | (1555.0) | (19.0) | |||
